Dr. Evan Stein joined Xenon's Board of Directors in April 2006, currently he serves as a consultant and advisor to a number of major pharmaceutical companies and biotechs including; Merck & Co., Schering-Plough, Novartis, AstraZeneca, Takeda, Roche and ISIS.
Dr. Stein is also a Director of the Cholesterol Treatment Center, a Director of the Metabolic and Atherosclerosis Research Center, and a Chief Scientific Officer of Medpace Reference Laboratories International. Dr. Stein has received a number of appointments to the National Institutes of Health (NIH) since 1986, including the GCRC Advisory Committee, the National Cholesterol Education Program, and various scientific review committees. He served on the Data and Safety Advisory Board of the National Heart, Lung, and Blood Institute Program on Genetics in Hypertension from 1999-2003.
Dr. Stein received his medical degree, as well as his PhD, from the University of Witwatersrand Medical School in Johannesburg, South Africa. In 1972 he started the first Lipid Clinic in South Africa, at the Transvaal Memorial Hospital for Children, and described the high gene frequency of Familial Hypercholesterolemia (FH). He completed his specialist training (FRCP) in Medical Biochemistry at McMaster University Medical Center in Canada prior to moving to the University of Cincinnati, Ohio, where he was on full-time faculty for 11 years, achieving the rank of Professor of Pathology and Laboratory Medicine as well as Associate Professor of Internal Medicine.